1 American Diabetes Association, 12. Children and Adolescents. Diabetes Care. 2017;40:105–13.
2 Diabetes Control and Complications Trial Research Group, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
3 Kaiserman K, et al. 20 Years of insulin lispro in pediatric type 1 diabetes: a review of available evidence. Pediatric Diabetes. 2017;18:81–94.
4 Harjutsalo V, Sund R, Knip M, Groop PH. Incidence of type 1 diabetes in Finland. JAMA. 2013;310:427–8.
5 Mayer-Davis EJ, et al. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012. N Engl J Med. 2017;376:1419–29.
6 Fourlanos S, et al. The rising incidence of type 1 diabetes is accounted for by cases with lower-risk human leukocyte antigen genotypes. Diabetes Care. 2008;31:1546–9.
7 Gardner SG, Bingley PJ, Sawtell PA, Weeks S, Gale EA. Rising incidence of insulin dependent diabetes in children aged under 5 years in the Oxford region: time trend analysis. The Bart’s-Oxford Study Group. BMJ. 1997;315:713–7.
8 Patterson C, et al. Diabetes in the young – a global view and worldwide estimates of numbers of children with type 1 diabetes. Diabetes Research and Clinical Practice. 2014;103:161–75.
9 Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. The Lancet (2014),
doi:10.1016/S0140-6736(13)60591-7.
10 Aguiree F, et al. IDF Diabetes Atlas : sixth edition (International Diabetes Federation, 2013).
11 Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G. Comparison of Insulin Aspart and Lispro. Diabetes Care. 2003;26:2027–31.
12 Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. 1994;43:396–402.
13 Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nature Publishing Group. 2017;13:385–99.
14 Heise T, et al. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab. 2015;17:682–8.
15 Fath M, et al. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus. Pediatric Diabetes. 2017;36:2035–8.
16 Schmidt S, Meldgaard M, Serifovski N, Storm C. Use of an automated bolus calculator in MDI-treated Type 1 diabetes the BolusCal Study, a randomized controlled pilot study (2012),
doi:10.2337/dc11-2044/-/DC1.
17 Ziegler R, et al. Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. Diabetes Care. 2013;36:3613–9.
18 Ziegler R, et al. Frequent use of an automated bolus advisor improves glycemic control in pediatric patients treated with insulin pump therapy: results of the Bolus Advisor Benefit Evaluation (BABE) study. Pediatric Diabetes. 2016;17:311–8.
19 Bally L, et al. Carbohydrate Estimation Supported by the GoCARB System in Individuals With Type 1 Diabetes: A Randomized Prospective Pilot Study. Diabetes Care. 2017;40:e6–e7.
20 Smart CE, et al. ISPAD Clinical Practice Consensus Guidelines 2014. Nutritional management in children and adolescents with diabetes. Pediatric Diabetes. 2017;15 Suppl 20:135–53.
21 American Diabetes Association, 6. Glycemic Targets. Diabetes Care. 2017;40:48–56.
22 Rewers MJ, et al. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatric Diabetes. 2014;15:102–14.
23 Acerini C, Craig ME, de Beaufort C, Maahs DM, Hanas R. Introduction to ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. Pediatric Diabetes. 2014;15 Suppl 20:1–3.
24 Donaghue KC, et al. Microvascular and macrovascular complications in children and adolescents. Pediatric Diabetes. 2014;15:257–69.
25 Roldán MB, Alonso M, Barrio R. Thyroid autoimmunity in children and adolescents with Type 1 diabetes mellitus. Diabetes Nutr. Metab. 1999;12:27–31.
26 Pham-Short A, et al. Screening for Celiac Disease in Type 1 Diabetes: A Systematic Review. PEDIATRICS. 2015;136:e170–e176.
27 Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. The Lancet. 1994;344:283–7.
28 Hauschild M, Bachmann S, Mullis P, Gozzi Graf T, Tonella P, Kuhlmann B, et al. Diabetische Kinder und Jugendliche in der Schule. Paediatrica. 2016;27(1):16–23.
swiss-paediatrics.org.
29 Katz ML, Volkening LK, Butler DA, Anderson BJ, Laffel LM. Family-based psychoeducation and care ambassador intervention to improve glycemic control in youth with type 1 diabetes: a randomized trial. Pediatric Diabetes. 2013;15:142–50.
30 Klocker AA, Phelan H, Twigg SM, Craig ME. Blood β-hydroxybutyrate vs. urine acetoacetate testing for the prevention and management of ketoacidosis in Type 1 diabetes: a systematic review. Diabet Med. 2013;30:818–24.
31 Matuleviciene V, et al. A clinical trial of the accuracy and treatment experience of the Dexcom G4 sensor (Dexcom G4 system) and Enlite sensor (guardian REAL-time system) tested simultaneously in ambulatory patients with type 1 diabetes. Diabetes Technology & Therapeutics. 2014;16:759–67.
32 Bonora B, Maran A, Ciciliot S, Avogaro A, Fadini GP. Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes. J. Endocrinol. Invest. (2016), doi:10.1007/s40618-016-0495-8.
33 Maahs DM, et al. Effect of Acetaminophen on CGM Glucose in an Outpatient Setting. Diabetes Care. 2015;38:e158–9.
34 the SWITCH Study Group et al., Impact of continuous glucose monitoring on quality of life, treatment satisfaction, and use of medical care resources: analyses from the SWITCH study. Acta Diabetol. 2014;51:845–51.
35 P. J. B. PhD, R. A. PhD, P. G.-D. PhD, J. K. PhD, R. W. MD. Articles Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. The Lancet, 1–10 (2016).
36 Guerci B, et al. Accuracy of an electrochemical sensor for measuring capillary blood ketones by fingerstick samples during metabolic deterioration after continuous subcutaneous insulin infusion interruption in type 1 diabetic patients. Diabetes Care. 2003;26:1137–41.
*37 Sherr JL, et al. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia. 2016;59:87–91.
38 Choudhary P. Insulin pump therapy with automated insulin suspension: toward freedom from nocturnal hypoglycemia. JAMA. 2013;310:1235–6.
39 Bergenstal RM, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369:224–32.
40 Buckingham BA, et al. Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis. Diabetes Care. 2015;38:1197–204.
41 Ly TT, et al. Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. Pediatric Diabetes, 1–8 (2016).
42 Anderson SM, et al. Multinational Home Use of Closed-Loop Control Is Safe and Effective. Diabetes Care. 2016;39:1143–50.
43 Garg SK, et al. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics. 2017;19:155–63.
44 Russell SJ, et al. Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes. N Engl J Med, 140615180011006 (2014).
*45 S. J. R. MD, et al. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. The Lancet Diabetes & Endocrinology. 2016;4:233–43.
46 Hirsch IB. Insulin analogues. N Engl J Med. 2005;352:174–83.
47 Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab. 2012;14:780–8.
48 Jennifer G, Christoph K, Jeremy P, Tim H. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. Current Medical Research and Opinion. 2017;0:1–27.